
Tetra Bio-Pharma closes $10M public offering to fund drug research
CEO Guy Chamberland told OBJ earlier this year firm is working on breakthrough treatments for sepsis and acute respiratory distress syndrome.
Tetra Bio-Pharma closes $10M public offering to fund drug research
CEO Guy Chamberland told OBJ earlier this year firm is working on breakthrough treatments for sepsis and acute respiratory distress syndrome.
Ottawa drug-maker Tetra Bio-Pharma’s decade-long research effort may be poised to pay off
Product is designed to treat life-threatening conditions triggered when the body’s immune system “goes rogue” in response to infections such as COVID-19.
Ottawa’s Tetra Bio-Pharma graduates to TSX
Bioscience firm that’s developing cannabinoid-based treatments for chronic pain is slated to move up from TSX Venture Exchange on Aug. 4.
Shareholders approve Ottawa-based Tetra Bio-Pharma’s $12M acquisition
Tetra Bio-Pharma’s shareholders are endorsing the local firm’s plans to accelerate its cannabidiol research efforts as excitement around the market for hemp-based products heats up.
Orléans-based Tetra Bio-Pharma acquires cannabinoid research firm in $12M deal
An east-end Ottawa research firm has acquired another pharmaceutical company working in the cannabinoid space, bolstering both its product pipeline and roster of researchers. Tetra
Get up-to-date news about the companies, people and issues that impact businesses in Ottawa and beyond.
Sponsored
EVENT ALERT: Mayor's Breakfast with Ontario Finance Minister on Wednesday, Dec. 4 @ City Hall